Sio Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Sio Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-251,900	Closed	-$33.1M	–	66
2021 Q2	$33.1M	Buy	+251,900	New	+$33.6M	8.24%	1

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Sio Capital Management's ASND Position: Q2 2020 in Review

Sio Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2020, closing a stake of 13,889 shares — an estimated $1.56M sold.

Sio Capital Management first reported a position in ASND in Q2 2015 and held it in 8 quarters. The position peaked at $10.6M in Q1 2019. 154 funds tracked by Wall St. Rank hold ASND as of Q2 2020.

Sio Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2020 after selling out during the quarter.
Sio Capital Management sold 13,889 Ascendis Pharma A/S shares in Q2 2020, an estimated $1.56M.
Sio Capital Management first reported a position in Ascendis Pharma A/S in Q2 2015 and held it in 8 quarters.
Sio Capital Management's Ascendis Pharma A/S position peaked at $10.6M in Q1 2019.
154 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2020.

Based on Sio Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.